[go: up one dir, main page]

PE20080053A1 - Composiciones oftalmicas de alcaftadina - Google Patents

Composiciones oftalmicas de alcaftadina

Info

Publication number
PE20080053A1
PE20080053A1 PE2007000398A PE2007000398A PE20080053A1 PE 20080053 A1 PE20080053 A1 PE 20080053A1 PE 2007000398 A PE2007000398 A PE 2007000398A PE 2007000398 A PE2007000398 A PE 2007000398A PE 20080053 A1 PE20080053 A1 PE 20080053A1
Authority
PE
Peru
Prior art keywords
alcaftadine
ophthalmic compositions
eye
ophthalmic
imidaze
Prior art date
Application number
PE2007000398A
Other languages
English (en)
Inventor
Jagdish Parasrampuria
Avner Ingerman
Frans Janssens
Anton Megens
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of PE20080053A1 publication Critical patent/PE20080053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION OFTALMICA QUE COMPRENDE DE 0,005% A 10% POR PESO DE ALCAFTADINA (6,11-DIHIDRO-11-(1-METIL-4-PIPERIDINILIDENO)-5H-IMIDAZO[2,1-b][3]BENZAZEPINA-3-CARBOXALDEHIDO) Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. DICHA FORMULACION SE PRESENTA BAJO LA FORMA DE SOLUCION O SUSPENSION OFTALMICA Y ES UTIL EN EL TRATAMIENTO DE ENROJECIMIENTO OCULAR, PICAZON OCULAR, HINCHAZON DE PARPADOS, QUEMOSIS, ENTRE OTRAS
PE2007000398A 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina PE20080053A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
PE20080053A1 true PE20080053A1 (es) 2008-03-10

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000398A PE20080053A1 (es) 2006-03-31 2007-04-02 Composiciones oftalmicas de alcaftadina

Country Status (29)

Country Link
US (8) US8664215B2 (es)
EP (2) EP3150209B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK2004196T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2594655T3 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL3150209T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI450721B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594655T3 (es) 2006-03-31 2016-12-21 Vistakon Pharmaceuticals, Llc Tratamiento de alergias oculares
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
MX2010005012A (es) * 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
PT3943069T (pt) 2009-03-17 2025-02-21 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2019026992A1 (ja) * 2017-08-03 2019-02-07 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
US20210128544A1 (en) 2018-01-18 2021-05-06 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CN115701988A (zh) * 2020-06-15 2023-02-14 阿尔克姆实验室有限公司 阿卡他定和皮质类固醇的组合
WO2022182740A1 (en) 2021-02-24 2022-09-01 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
MX2023011546A (es) 2021-04-01 2023-10-06 Alkem Laboratories Ltd Composiciones nasales que comprenden alcaftadina.
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
TW202408472A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
CN116473937A (zh) * 2022-11-29 2023-07-25 嘉兴学院 一种具有抗恶性黑素瘤作用的仿生纳米颗粒及制备方法和应用
JPWO2024204749A1 (es) * 2023-03-31 2024-10-03

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
JPH089616B2 (ja) 1990-10-10 1996-01-31 シェリング・コーポレーション 置換されたイミダゾベンズアゼピン類およびイミダゾピリドアゼピン類
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN101420934B (zh) 2006-03-17 2014-03-19 庄臣及庄臣视力保护公司 用于使氧化不稳定的组合物稳定的方法
ES2594655T3 (es) 2006-03-31 2016-12-21 Vistakon Pharmaceuticals, Llc Tratamiento de alergias oculares

Also Published As

Publication number Publication date
DK2004196T3 (en) 2016-09-05
KR20080110881A (ko) 2008-12-19
US8664215B2 (en) 2014-03-04
NZ571690A (en) 2011-09-30
PL2004196T3 (pl) 2017-01-31
UY30254A1 (es) 2007-08-31
NI200800261A (es) 2012-10-30
DK3150209T3 (da) 2019-10-28
JP2013144703A (ja) 2013-07-25
EA016221B1 (ru) 2012-03-30
ES2752823T3 (es) 2020-04-06
PL3150209T3 (pl) 2020-03-31
AR060278A1 (es) 2008-06-04
JP2015131820A (ja) 2015-07-23
BRPI0710085B1 (pt) 2019-12-17
CA2648115C (en) 2015-03-24
TWI578990B (zh) 2017-04-21
AU2007234957B2 (en) 2012-12-13
JO3358B1 (ar) 2019-03-13
IL194473A (en) 2016-04-21
JP6039716B2 (ja) 2016-12-07
CL2007000916A1 (es) 2008-01-25
IL194473A0 (en) 2009-08-03
EP2004196B1 (en) 2016-06-29
US20210030762A1 (en) 2021-02-04
US20140107102A1 (en) 2014-04-17
JP5292277B2 (ja) 2013-09-18
CN102895234A (zh) 2013-01-30
EP3150209B1 (en) 2019-07-24
CA2648115A1 (en) 2007-10-18
KR101321731B1 (ko) 2013-10-30
MY153669A (en) 2015-03-13
MX2008012657A (es) 2009-02-19
ES2594655T3 (es) 2016-12-21
HK1131331A1 (en) 2010-01-22
ZA200809327B (en) 2009-12-30
US20240058355A1 (en) 2024-02-22
BRPI0710085A2 (pt) 2011-08-23
TWI450721B (zh) 2014-09-01
EP3150209A1 (en) 2017-04-05
US20250108059A1 (en) 2025-04-03
EA200870396A1 (ru) 2009-04-28
US10617695B2 (en) 2020-04-14
TW201446249A (zh) 2014-12-16
US20080051385A1 (en) 2008-02-28
US20230181594A1 (en) 2023-06-15
ECSP088786A (es) 2009-01-30
EP2004196A2 (en) 2008-12-24
NO20084593L (no) 2008-10-29
TW200815016A (en) 2008-04-01
CR10414A (es) 2009-02-23
US20170065605A1 (en) 2017-03-09
NO341147B1 (no) 2017-09-04
JP2009533333A (ja) 2009-09-17
SG170044A1 (en) 2011-04-29
WO2007117971A3 (en) 2007-12-27
US20120094978A1 (en) 2012-04-19
WO2007117971A2 (en) 2007-10-18
AU2007234957A1 (en) 2007-10-18
BRPI0710085B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
BRPI0512569A (pt) métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
CL2009000400A1 (es) Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
MA31953B1 (fr) Nouveaux derives du thiophene.
PE20110287A1 (es) Composiciones oftalmicas que comprenden riboflavina en combinacion con la asociacion de edta y trometamina, o en combinacion con fotointensificadores
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
CL2007003821A1 (es) Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras.
CL2007001178A1 (es) Compuestos fusionados derivados de tetrahidro[1,2,4]triazol[4,3-a]pirimidina, moduladores de receptores de glutamato metabotropicos (mglur5); compuestos intermediarios; composicion y combinacion farmaceutica que los comprende; y su uso en la preparacion de medicamentos para tratar enfermedades gastroesofagicas, la ansiedad y dolores.
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
RU2012103538A (ru) Композиции и способы ингибирования пути jak
NO20074036L (no) Anvendelse av cyaninfargestoffer for diagnose av proliferative sykdommer
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
GT200900173A (es) Dispersión sólida de un antagonista de neuroquinina
MX2010000130A (es) Derivados de 3-espiropirimidintriona-quinolina y su uso como agentes antibacterianos.
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
AR079683A1 (es) Formulacion topica oftalmica de peptidos
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon

Legal Events

Date Code Title Description
FG Grant, registration